Environmental Testing Standards
Inorganic Ventures CCV ICV SOLUTION 3 125mL
Inorganic Ventures' CICV Standard 3 is a 125mL certified reference material set in a nitric acid matrix for stability. This standard is Traceable to NIST and manufactured in accordance with our stringent Quality Assurance guidelines. See Certificate of Analysis for expiration.
ATTENTION: Inorganic Ventures is no longer supplying paper copies of Certificate of Analyses(CoA) and Safety Data Sheets (SDS). Please use this link to download your copies: https://www.inorganicventures.com/coa-sds-search
Inorganic Ventures INSTR PERFORM CHECK 2 125mL
Matrix: Nitric Acid / Hydrofluoric Acid (HNO3 / HF), Dilution: 1:100, Analyte: Sb, Ti, Mo, and Sn 200 ug/mL each, and SiO2 1000 ug/mL.
ATTENTION: Inorganic Ventures is no longer supplying paper copies of Certificate of Analyses(CoA) and Safety Data Sheets (SDS). Please use this link to download your copies: https://www.inorganicventures.com/coa-sds-search
Inorganic Ventures 200.7WW CAL SOLUTION 1A 125mL
Matrix: Nitric Acid (HNO3), Dilution: 1:100, Analyte: Ag 50 ug/mL, Ba, B, Sr 100 ug/mL each, Cd, Cu, Mn 200 ug/mL each, Se 500 ug/mL, As and Mn 1000 ug/mL each.
ATTENTION: Inorganic Ventures is no longer supplying paper copies of Certificate of Analyses(CoA) and Safety Data Sheets (SDS). Please use this link to download your copies: https://www.inorganicventures.com/coa-sds-search
Inorganic Ventures 6020 INTERFER CHK SOLN B 125mL
Inorganic Ventures' 6020 Rev-0 Interference Check Standard B is a 125mL certified reference material set in a nitric acid matrix for stability. This standard is Traceable to NIST and manufactured in accordance with our stringent Quality Assurance guidelines. See Certificate of Analysis for expiration.
ATTENTION: Inorganic Ventures is no longer supplying paper copies of Certificate of Analyses(CoA) and Safety Data Sheets (SDS). Please use this link to download your copies: https://www.inorganicventures.com/coa-sds-search
PHENOVA PFAS CRM FOR EPA 537.1,
Description: PFAS CRM for EPA 537.1 mix, 2 µg/mL in methanol, EaStandard Type: Calibration Standard
![eMolecules ChemScene / Ethyl 3-oxo-23-dihydrofuro[23-b]pyridine-2-carboxylate / 250mg / 632277545 / CS-0042833 / 0.000 / 1279893-97-8 / MFCD18074430 / 207.185 / C10H9NO4](https://assets.fishersci.com/TFS-Assets/CCG/product-images/502440911.PNG-250.jpg)
eMolecules ChemScene / Ethyl 3-oxo-23-dihydrofuro[23-b]pyridine-2-carboxylate / 250mg / 632277545 / CS-0042833 / 0.000 / 1279893-97-8 / MFCD18074430 / 207.185 / C10H9NO4
ChemScene / Ethyl 3-oxo-23-dihydrofuro[23-b]pyridine-2-carboxylate / 250mg / 632277545 / CS-0042833 / 0.000 / 1279893-97-8 / MFCD18074430 / 207.185 / C10H9NO4
eMolecules Ambeed / Methyl 2-acetoxybenzoate / 25g / 642080640 / A369424 / / 580-02-9 / MFCD00014978 / 194.186 / C10H10O4
Ambeed / Methyl 2-acetoxybenzoate / 25g / 642080640 / A369424 / / 580-02-9 / MFCD00014978 / 194.186 / C10H10O4
Medchemexpress LLC Cys modifier 1 | 2374314-08-4 | 99.0% | 381.34 | 50 MG
Cys modifier 1 is a cysteine-selective protein modifier utilized for protein bioconjugation. It is a fluorescent carbonylacrylic derivative that bears nitrobenzofurazan (λex=465nm and λem=539 nm).
- Cysteine-selective protein modification
- Fluorescent carbonylacrylic derivative
- Bears nitrobenzofurazan for fluorescence (λex=465nm and λem=539 nm)
- Target: Fluorescent dye
- Pathway: Others
Apexbio Technology LLC Diclofenac 15307-86-5 10g
Diclofenac (CAS 15307-86-5) is a phenylacetic acid derivative classified as a non-steroidal anti-inflammatory drug (NSAID) It exerts its biological activity by inhibiting cyclooxygenase (COX)-1 and COX-2 enzymes thereby suppressing prostaglandin synthesis that mediates inflammation and pain signaling Structurally the incorporation of two ortho chlorine atoms on the phenyl ring increases molecular rigidity which has been associated with enhanced potency Diclofenac is widely used in research to study inflammatory pathways pain mechanisms and as a reference compound in the evaluation of cyclooxygenase inhibition and potential gastrointestinal protective strategies in combination therapies